At GAIA we are focused on the development of evidence-based, safe and accessible digital therapeutics that help patients restore and maintain their mental and physical health.

Our mission is to develop digital therapeutics that offer physicians, therapists, payers and patients the same effect sizes, similar safety profiles and equal levels of convenience as found in well-developed, pharmaceutical solutions.

With a team of multidisciplinary experts, we cover all competencies required to develop, launch and maintain top-of-class products for major markets. Our team includes experienced physicians and psychotherapists, clinical scientists experienced in orchestrating Phase II & III trials, IT and software engineers, regulatory affairs experts as well as market access specialists.

We believe that RCT-evidence is key. This is why our digital therapeutics are extensively tested in unbiased, ethical and professionally designed randomized controlled trials (RCTs). One of our most researched products is deprexis®, the online program for the treatment of depression, shown to effectively reduce symptoms in 13 randomized controlled trials with effect sizes similar to antidepressants.